FeesSafety
Pluang+

FDA clears Medtronic's Hugo robotic system for general surgery in the U.S., expanding its use beyond urology.

Market News
17 Nov 2026, 13:00 WIB
PRNewsWire
View Source
Bullish
FDA clears Medtronic's Hugo robotic system for general surgery in the U.S., expanding its use beyond urology.

Medtronic's Hugo robotic-assisted surgery system has received FDA clearance for a wide range of general surgery procedures in the U.S., including upper and lower abdominal surgeries like cholecystectomy and hernia repair. This approval allows the system to be used in procedures accounting for over 3.5 million surgeries annually, significantly broadening its application beyond urology. The system's modular design offers flexibility for surgical teams, and it integrates trusted Medtronic technology to enhance precision and outcomes. This expansion supports hospitals in addressing capacity challenges and improving patient care options with advanced robotic surgery.

Medtronic PLC (MDT) shares trade at USD 103.51 on Pluang as of Nov 17, 2026, 18:11 WIB, up 0.61% for the day. The stock is near its 52-week high of USD 105.35, with a market cap of $131.60 billion. Pluang investors show strong interest, with 100% buy orders and a typical hold time of 65 days.

More News (MDT)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App